{"id":"hr","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug-induced lupus"}]},"_chembl":null,"_dailymed":{"setId":"380d7f6d-cdfe-4a22-a6e0-13fe2ae12e6c","title":"CHILDRENS 12 HR COUGH RELIEF (DEXTROMETHORPHAN POLISTIREX) SUSPENSION [CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid inhibits mycolic acid synthesis in the mycobacterial cell wall, while rifampicin inhibits bacterial RNA polymerase. Together, these first-line anti-tuberculosis agents provide synergistic bactericidal activity against Mycobacterium tuberculosis. The combination is a standard component of TB treatment regimens.","oneSentence":"HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:09:33.815Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"}]},"trialDetails":[{"nctId":"NCT07498400","phase":"NA","title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-01","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer","enrollment":216},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT07494383","phase":"NA","title":"Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial","status":"COMPLETED","sponsor":"ISSSTE Hospital Regional \"Gral. Ignacio Zaragoza\"","startDate":"2024-05-21","conditions":"Post-Dural Puncture Headache, Headache","enrollment":26},{"nctId":"NCT07424547","phase":"PHASE1","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2026-03-03","conditions":"Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer","enrollment":386},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT07498413","phase":"","title":"Epidemiology and Treatment of HR+/HER2- Breast Cancer in England","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-08","conditions":"Breast Cancer","enrollment":218677},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT07113288","phase":"","title":"Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study","status":"RECRUITING","sponsor":"Inspire Medical Systems, Inc.","startDate":"2025-07-31","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":70},{"nctId":"NCT05727930","phase":"NA","title":"Variable Intensive Early Walking Post-Stroke - 2 (VIEWS-2)","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-01-11","conditions":"Stroke","enrollment":100},{"nctId":"NCT06726148","phase":"PHASE1, PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors","enrollment":280},{"nctId":"NCT00001309","phase":"PHASE1","title":"The Body's Affect on Vitamin C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-01-23","conditions":"Healthy Volunteers","enrollment":23},{"nctId":"NCT07383506","phase":"PHASE1","title":"A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cogent Biosciences, Inc.","startDate":"2026-02","conditions":"PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer","enrollment":90},{"nctId":"NCT05514405","phase":"NA","title":"Effect of Remimazolam and Propofol on Postoperative Delirium","status":"RECRUITING","sponsor":"Inje University","startDate":"2022-08-01","conditions":"Hip Fractures, Knee Osteoarthritis, Femur Fracture","enrollment":82},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT07387523","phase":"NA","title":"Psychological and Lifestyle Factors That Predict Adherence of Multi-domain Interventions for Promoting Brain Health","status":"ENROLLING_BY_INVITATION","sponsor":"Institut Guttmann","startDate":"2026-02-15","conditions":"Brain Health Activities, Cognition, Prevention","enrollment":120},{"nctId":"NCT07497386","phase":"PHASE2","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT06579807","phase":"NA","title":"Cardiac Rehabilitation and Coronary Artery Disease","status":"RECRUITING","sponsor":"Instituto Nacional de Cardiologia de Laranjeiras","startDate":"2024-10-01","conditions":"Coronary Artery Disease, Atherosclerosis","enrollment":50},{"nctId":"NCT05697770","phase":"PHASE3","title":"SODium BICarbonate for Metabolic Acidosis in the ICU","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2023-04-26","conditions":"Metabolic Acidosis, Shock","enrollment":500},{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":"HR+/HER2- Breast Cancer","enrollment":1056},{"nctId":"NCT05072314","phase":"PHASE3","title":"Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-07-27","conditions":"Breast Cancer, Breast Cancer Female, Breast Conserving Surgery","enrollment":4300},{"nctId":"NCT07493824","phase":"PHASE4","title":"Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-07-24","conditions":"Persistent HR-HPV Infection of the Cervix","enrollment":115},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":"Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT07492394","phase":"PHASE2","title":"Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-12","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT06767566","phase":"PHASE1","title":"Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery","status":"RECRUITING","sponsor":"Grace Lim, MD, MS","startDate":"2025-03-28","conditions":"Pain, Postpartum Depression","enrollment":50},{"nctId":"NCT07404787","phase":"NA","title":"Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization","status":"RECRUITING","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2026-02-24","conditions":"Suicide, Suicide Attempt","enrollment":1500},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT06762483","phase":"","title":"Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-12-20","conditions":"Breast Cancer, Metastatic","enrollment":80},{"nctId":"NCT00001987","phase":"","title":"Genetic Studies of Insulin and Diabetes","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1976-02-01","conditions":"Diabetes Mellitus, Severe Insulin Resistance","enrollment":1200},{"nctId":"NCT07491705","phase":"NA","title":"Camel Milk Impact on Aerobic Exercise Recovery, Induced Inflammation, and Physical Performance","status":"COMPLETED","sponsor":"United Arab Emirates University","startDate":"2024-04-30","conditions":"Healthy","enrollment":12},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT07001605","phase":"NA","title":"Erector Spinae Block Vs Ketamine-based Multimodal Analgesia Protocol in Lumber Decompressive Surgery","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2025-06-20","conditions":"Spinal Decompression, Analgesia, Erector Spinae Plane Block","enrollment":62},{"nctId":"NCT07488169","phase":"NA","title":"The Role of Physical Ardor in Triggering State Anattā and Psychophysiological Recovery","status":"COMPLETED","sponsor":"Lincoln University College","startDate":"2025-04-01","conditions":"Psychological Stress, Mental Fatigue, Self-Perception","enrollment":671},{"nctId":"NCT05091905","phase":"PHASE4","title":"Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Diego","startDate":"2022-02-14","conditions":"Pain, Acute Postoperative, Trauma Injury","enrollment":140},{"nctId":"NCT07480889","phase":"PHASE3","title":"Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-03-18","conditions":"Hemodynamic (MAP) Stability","enrollment":100},{"nctId":"NCT05963997","phase":"PHASE1, PHASE2","title":"A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-10-09","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer","enrollment":49},{"nctId":"NCT02573896","phase":"PHASE1","title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2019-01-14","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT07486843","phase":"PHASE4","title":"Preventing Structural Damage in Early Psoriatic Arthritis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":108},{"nctId":"NCT07109726","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","status":"RECRUITING","sponsor":"Terremoto Biosciences Inc.","startDate":"2025-09-23","conditions":"Breast Cancer, Endometrial Cancer, Ovarian Cancer","enrollment":205},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT07347600","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-01-21","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT07485400","phase":"NA","title":"Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Universidad Complutense de Madrid","startDate":"2026-03-17","conditions":"Stable Coronary Artery Disease (CAD), Myocardial Infarction","enrollment":48},{"nctId":"NCT05720117","phase":"PHASE1","title":"A Study of PYX-201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pyxis Oncology, Inc","startDate":"2023-03-14","conditions":"Solid Tumor, Advanced Solid Tumor","enrollment":330},{"nctId":"NCT05967364","phase":"NA","title":"Career Enhancement Training Study Delivered Across Career Phases","status":"ENROLLING_BY_INVITATION","sponsor":"University of Rochester","startDate":"2025-01-27","conditions":"Suicide Prevention, Suicide","enrollment":2970},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT06966453","phase":"PHASE1, PHASE2","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-06-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":100},{"nctId":"NCT07484763","phase":"","title":"Predicting Recurrence in HR+/HER2- Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2026-04-01","conditions":"Breast Cancer, HR+/HER2- Early-Stage","enrollment":500},{"nctId":"NCT07136922","phase":"PHASE1","title":"First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency","status":"NOT_YET_RECRUITING","sponsor":"Calla Lily Clinical Care Ltd","startDate":"2026-04","conditions":"Luteal Phase Insuffiency, Progesterone Delivery","enrollment":20},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT05776316","phase":"NA","title":"Harm Reduction Services","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-11-25","conditions":"Drug Use, Substance Abuse, Mental Illness","enrollment":200},{"nctId":"NCT07484087","phase":"NA","title":"Ablation Compare With Surgery for Early Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Breast Cancer, Early Stage, Hormone Receptor Positive","enrollment":264},{"nctId":"NCT06900140","phase":"PHASE3","title":"Adjunctive Methylene Blue in Septic Shock","status":"COMPLETED","sponsor":"Dr. Shannon M. Fernando","startDate":"2025-06-02","conditions":"Septic Shock","enrollment":50},{"nctId":"NCT06417801","phase":"","title":"Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":"Metastatic Breast Cancer","enrollment":70},{"nctId":"NCT06395636","phase":"NA","title":"Early Detection of Infection Using the Fitbit in Pediatric Surgical Patients","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2025-01-07","conditions":"Appendectomy, Appendicitis, Appendicitis Acute","enrollment":500},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT04030507","phase":"NA","title":"Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-26","conditions":"Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer","enrollment":214},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05275439","phase":"PHASE1","title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML","status":"TERMINATED","sponsor":"Shattuck Labs, Inc.","startDate":"2022-03-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":106},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":"Esophageal Neoplasms, Gastro-esophageal Junction Cancer","enrollment":106},{"nctId":"NCT06833853","phase":"","title":"A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Menarini Silicon Biosystems, INC","startDate":"2026-03-13","conditions":"Metastatic Breast Cancer (MBC)","enrollment":187},{"nctId":"NCT07481461","phase":"NA","title":"Altered Joint Mechanics and Biological Response in Osteoarthritic Knees.","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-04","conditions":"Knee Osteoarthritis (OA)","enrollment":30},{"nctId":"NCT07153003","phase":"PHASE4","title":"Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2026-02-02","conditions":"Post Operative Pain","enrollment":560},{"nctId":"NCT07184801","phase":"PHASE3","title":"Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-10-01","conditions":"Medical Thoracoscopy","enrollment":56},{"nctId":"NCT07480304","phase":"NA","title":"To Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laeyngoscopy and Intubation in Patients Undergoing Elective Intubation","status":"ENROLLING_BY_INVITATION","sponsor":"Dow University of Health Sciences","startDate":"2025-12-01","conditions":"Evaluate Effect of Nebulized Dexmedetomedine Upon Blunting Autonomic Response of Laryngoscopy and Intubation in Patients Undergoing Elective Intubation","enrollment":36},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT07476170","phase":"","title":"Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-25","conditions":"HR+/HER2- Advanced or Metastatic Breast Cancer","enrollment":14000},{"nctId":"NCT03590171","phase":"PHASE2","title":"International Study for Treatment of High Risk Childhood Relapsed ALL 2010","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2017-09-01","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":250},{"nctId":"NCT07477392","phase":"NA","title":"Effect of Two Different Fluid Treatment Regimens on Ultrasonographic Upper Airway Measurements","status":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","startDate":"2023-03-01","conditions":"Goal-directed Fluid Theraphy, Upper Airway Ultrasonography","enrollment":145},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":"Advanced Solid Tumors, Breast Cancer, Breast Carcinoma","enrollment":134},{"nctId":"NCT06446739","phase":"NA","title":"LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-14","conditions":"Acute Kidney Injury, Dialysis; Complications","enrollment":100},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT06650748","phase":"PHASE2","title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-05-01","conditions":"Breast Cancer, Early-stage Breast Cancer","enrollment":100},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT05159427","phase":"PHASE1","title":"Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-03-15","conditions":"Human Gastrointestinal Physiology Data","enrollment":40},{"nctId":"NCT07218562","phase":"PHASE2","title":"PATH (Peer Advanced Training in Harm Reduction) to Reducing Burnout Among Peers Who Deliver Harm Reduction Services (R61 Phase Pilot)","status":"ENROLLING_BY_INVITATION","sponsor":"Chestnut Health Systems","startDate":"2026-01-12","conditions":"Burnout, Compassion Satisfaction, Secondary Trauma","enrollment":100},{"nctId":"NCT07475156","phase":"PHASE4","title":"The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-08-01","conditions":"Post Operative Delerium","enrollment":100},{"nctId":"NCT07393282","phase":"PHASE3","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-25","conditions":"High Risk Smoldering Multiple Myeloma (HR-SMM)","enrollment":270},{"nctId":"NCT04529304","phase":"NA","title":"EEG-based Depth of Anesthesia-monitoring, Effects on Dosage and Cognition","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-01-08","conditions":"Postoperative Complications, Delayed Emergence From Anesthesia, Cognitive Dysfunction","enrollment":100},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT05697146","phase":"","title":"Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-13","conditions":"Breast Cancer","enrollment":1019},{"nctId":"NCT07237256","phase":"PHASE3","title":"Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-18","conditions":"Breast Cancer","enrollment":3902},{"nctId":"NCT06930859","phase":"","title":"Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-22","conditions":"Breast Cancer","enrollment":2766},{"nctId":"NCT07471750","phase":"NA","title":"Acquisition and Clinical Image Evaluation of Fujifilm's High Resolution (HR) Digital Breast Tomosynthesis (DBT) Images.","status":"NOT_YET_RECRUITING","sponsor":"Fujifilm Medical Systems USA, Inc.","startDate":"2026-03-30","conditions":"Routine Screening Mammography","enrollment":18},{"nctId":"NCT06994676","phase":"PHASE1","title":"A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias","status":"RECRUITING","sponsor":"Crossbow Therapeutics, Inc.","startDate":"2025-07-16","conditions":"High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia","enrollment":72},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07368998","phase":"PHASE2","title":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-02-18","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06325280","phase":"","title":"Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2025-01-20","conditions":"Pediatric ALL, Congenital Heart Disease, Heart Transplantation","enrollment":20},{"nctId":"NCT03876769","phase":"PHASE2","title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-24","conditions":"B-Cell Acute Lymphoblastic Leukemia","enrollment":121}],"_emaApprovals":[],"_faersSignals":[{"count":15695,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":7854,"reaction":"ACUTE KIDNEY INJURY"},{"count":6056,"reaction":"RENAL FAILURE"},{"count":5649,"reaction":"RENAL INJURY"},{"count":5048,"reaction":"END STAGE RENAL DISEASE"},{"count":1758,"reaction":"TUBULOINTERSTITIAL NEPHRITIS"},{"count":1615,"reaction":"INCORRECT DOSE ADMINISTERED"},{"count":1176,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":1172,"reaction":"NEPHROGENIC ANAEMIA"},{"count":1135,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[{"date":"20240118","type":"SUPPL","sponsor":"GRANULES","applicationNumber":"ANDA211544"},{"date":"20190416","type":"ORIG","sponsor":"GRANULES","applicationNumber":"ANDA211544"},{"date":"20240919","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20240919","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20120518","type":"ORIG","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20200820","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20130405","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20240919","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20130405","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20200820","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20150918","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA202319"},{"date":"20141021","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA076050"},{"date":"20040922","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA076050"},{"date":"20040728","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA076050"},{"date":"20030130","type":"ORIG","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA076050"},{"date":"20050621","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA076050"},{"date":"20210825","type":"ORIG","sponsor":"MARKSANS PHARMA","applicationNumber":"ANDA215486"},{"date":"19940608","type":"ORIG","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20010212","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"19950105","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20190116","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"19941123","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20130328","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20160826","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20111223","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20141223","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20100510","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20140306","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20040413","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20090918","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20030801","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20030528","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20010111","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20030529","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20000725","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"19950728","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20131220","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20130326","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20080228","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20160505","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20141212","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20100506","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20040322","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20090617","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20000725","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20041103","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"20030528","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"},{"date":"19950801","type":"SUPPL","sponsor":"KENVUE BRANDS","applicationNumber":"NDA019872"}],"publicationCount":384075,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["isoniazid","H","rifampicin","R"],"phase":"marketed","status":"active","brandName":"HR","genericName":"HR","companyName":"Global Alliance for TB Drug Development","companyId":"global-alliance-for-tb-drug-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis. Used for Tuberculosis (pulmonary and extrapulmonary).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}